TABLE 3.
Sensitivity analysis including patients who received Impella for high-risk percutaneous coronary intervention
| Unmatched cohorts |
Matched cohorts |
|||||||
|---|---|---|---|---|---|---|---|---|
| Variables no. (%) | Female (n = 2,185) | Male (n = 5,535) | Total (n = 7,720) | p-value | Female (n = 2,143) | Male (n = 2,238) | Total (n = 4,381) | p-value |
| In-hospital outcomes | ||||||||
| Major adverse events | 13.2 | 7.9 | 9.4 | <.01 | 13.2 | 8.7 | 10.9 | <.01 |
| Death | 6.7 | 4.6 | 5.2 | .01 | 6.7 | 5.5 | 6.1 | .19 |
| Vascular complications | 2.7 | 2.3 | 2.4 | .50 | 2.7 | 2 | 2.3 | .34 |
| Major bleeding | 5.6 | 2.1 | 3.1 | <.01 | 5.5 | 2.1 | 3.8 | <.01 |
|
| ||||||||
| Severe disability surrogates | ||||||||
| Nonhome discharge | 20.1 | 11.5 | 13.9 | <.01 | 19.9 | 12.6 | 16.1 | <.01 |
| Mechanical ventilation | 7.6 | 6.9 | 7.1 | .50 | 7.6 | 7 | 7.3 | .62 |
|
| ||||||||
| Resources utilization | ||||||||
| Length of hospitalization | 6 | 5 | 5 | <.01 | 6 | 5 | 5 | <.01 |
| Median days (25th–75th IQR) | 3-11 | 2-9 | 2-9 | – | 3-11 | 2-9 | 2-10 | – |
| Cost of hospitalization | 55,036 | 52,000 | 52,692 | <.01 | 55,010 | 52,653 | 53,743 | .01 |
| Median $ (25th–75th IQR) | (41,571–73,092) | (39,209–68,369) | (39,726–69,801) | – | (41,604–73,011) | (39,327–69,854) | (40,427–71,540) | – |
Abbreviation: IQR, interquartile range.